BioAge Labs, Inc. — Form 8-K Summary
Filing date and event: October 2, 2026. This is a clinical-development update, not a periodic financial report.
Business context and trial update
BioAge announced that the first participant was dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (DME).
- The trial plans to enroll approximately 180 participants, randomized equally among three arms, with 12 weeks of daily dosing and four weeks of follow-up.
- Arms: intravitreal anti-VEGF plus oral placebo; anti-VEGF plus 90 mg BGE-102; or simulated intravitreal injection plus 90 mg BGE-102.
- The primary endpoint is change in best-corrected visual acuity at week 12. Exploratory endpoints include retinal measures and intraocular and plasma biomarkers.
Financial metrics and period comparison
This 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results. It does not provide a comparable-period financial update.
Outlook, risks, and contingencies
Topline QUELL-DME results are expected in the second half of 2027. BioAge says the results are expected to inform development strategy for other NLRP3-driven retinal diseases, including geographic atrophy. These are forward-looking statements, not guarantees.
The filing highlights risks including clinical-trial timing and outcomes, safety events, regulatory delays or additional study requirements, development and commercialization challenges, reliance on third parties, access to capital, and other risks described in the company’s SEC filings.
Important facts for investors to verify
- Enrollment progress and whether the planned approximate 180-participant sample size is achieved.
- Trial conduct, safety findings, and the timing and results of the week-12 primary endpoint.
- Whether the expected second-half 2027 topline timeline changes.
- Financial position and cash runway in the company’s periodic filings; this 8-K does not report them.